Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

Abstract excerpt

OBJECTIVE: To evaluate PIK3CA mutational status and c-erbB2 gene amplification in a series of primary uterine serous carcinomas (USC) cell lines. To assess the efficacy of GDC-0980, a potent inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2), against primary USC harboring HER2/neu gene amplification and/or PIK3CA mutations. STUDY DESIGN: Twenty-two primary USC cell lines were evaluated for c-erbB2 oncogene...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bridged Bicyclo Compounds, Heterocyclic
• Share to Carcinoma, Papillary